These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 30860573)

  • 1. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
    Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
    Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
    Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M
    Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
    Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
    J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    O'Leary B; Cutts RJ; Huang X; Hrebien S; Liu Y; André F; Loibl S; Loi S; Garcia-Murillas I; Cristofanilli M; Bartlett CH; Turner NC
    J Natl Cancer Inst; 2021 Mar; 113(3):309-317. PubMed ID: 32940689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
    Darrigues L; Pierga JY; Bernard-Tessier A; Bièche I; Silveira AB; Michel M; Loirat D; Cottu P; Cabel L; Dubot C; Geiss R; Ricci F; Vincent-Salomon A; Proudhon C; Bidard FC
    Breast Cancer Res; 2021 Mar; 23(1):31. PubMed ID: 33676547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
    Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
    Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
    Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
    Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B
    Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
    Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
    Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study.
    Sabatier R; Vicier C; Garnier S; Guille A; Carbuccia N; Isambert N; Dalenc F; Robert M; Levy C; Pakradouni J; Adelaïde J; Chaffanet M; Sfumato P; Mamessier E; Bertucci F; Goncalves A
    Mol Oncol; 2022 May; 16(10):2057-2070. PubMed ID: 35122700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
    Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
    JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
    Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
    Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
    Sharma P; Abramson VG; O'Dea A; Nye L; Mayer I; Pathak HB; Hoffmann M; Stecklein SR; Elia M; Lewis S; Scott J; De Jong JA; Wang YY; Yoder R; Schwensen K; Finke K; Heldstab J; LaFaver S; Williamson SK; Phadnis MA; Reed GA; Kimler BF; Khan QJ; Godwin AK
    Clin Cancer Res; 2021 Jul; 27(14):3896-3904. PubMed ID: 33602685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
    Bos MK; Lam SW; Motta G; Helmijr JCA; Beaufort CM; de Jonge E; Martens JWM; Boven E; Jansen MPHM; Jager A; Sleijfer S
    Breast Cancer Res Treat; 2023 Jul; 200(2):271-279. PubMed ID: 37226020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study.
    Allsopp RC; Guo Q; Page K; Bhagani S; Kasim A; Badman P; Kenny L; Stebbing J; Shaw JA
    Breast Cancer Res Treat; 2024 Jul; 206(2):377-385. PubMed ID: 38581534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.